Allogene Therapeutics Reports Narrowed Q2 Loss Despite Clinical Trial Delays for CAR-T Programs
核心洞察
Allogene Therapeutics narrowed its GAAP net loss to $0.23 per share in Q2 2025, beating estimates of $0.27 per share while maintaining a strong cash position of $302.6 million.
The company delayed key clinical trial timelines for its lymphoma and autoimmune disease programs by approximately two quarters due to operational challenges at trial sites.
Over 250 patients have been consented for screening across trials, with the ALPHA3 futility analysis for cema-cel now expected in the first half of 2026.
Allogene Therapeutics reported improved financial performance for the second quarter of 2025, narrowing its GAAP net loss to $0.23 per share compared to $0.35 per share in the same period last year. The clinical-stage biotechnology company, which develops off-the-shelf chimeric antigen receptor T cell (CAR-T) therapies, beat analyst estimates of $0.27 per share while maintaining a robust cash position to fund operations through 2027.
Despite the financial improvements, the company announced delays of approximately two quarters for key clinical trial milestones across its lymphoma and autoimmune disease programs, citing operational challenges at trial sites and complex logistics requirements.
Strong Financial Position Amid Development Delays
The company ended Q2 2025 with $302.6 million in cash, cash equivalents, and investments, down from $373.1 million at the end of Q4 2024. Management reaffirmed that this funding should support operations into the second half of 2027, even as clinical development spending remains significant.
Research and development expenses totaled $40.2 million for the quarter, including $2.6 million in non-cash stock-based compensation. General and administrative expenses were $14.3 million, which included $6.1 million of non-cash stock-based compensation expense.
The company maintained its 2025 guidance, projecting GAAP operating expenses of approximately $230 million and an expected decrease in cash of approximately $150 million for the year.
ALPHA3 Trial Progress and Timeline Adjustments
Allogene's lead program, cema-cel, is being evaluated in the ALPHA3 trial for first-line treatment of large B-cell lymphoma (搜索) (LBCL). The trial has seen significant patient interest, with over 250 patients consented for screening since trial activation, including about half of this number in the past three months as of Q1 2025.
However, delays in site activation and patient conversion have pushed the timeline for a key internal review, including futility analysis and lymphodepletion regimen selection, from late 2025 into the first half of 2026. The company expects to provide rates of minimal residual disease (MRD) conversion between the two treatment arms at the time of this announcement.
To date, over 50 clinical sites are activated across the United States and Canada, including community cancer centers and major academic institutions. Management noted that site engagement has improved recently, with international trial expansion expected to accelerate enrollment and strengthen trial execution.
Autoimmune Disease Program Launches with Delays
The Phase 1 RESOLUTION basket trial for ALLO-329 launched in Q2 2025, representing a significant step in evaluating CAR-T therapy across multiple autoimmune conditions, including systemic lupus erythematosus (搜索), idiopathic inflammatory myopathies (搜索), and systemic sclerosis (搜索).
ALLO-329 is described as a first-in-class allogeneic CD19 (搜索)/CD70 (搜索) dual CAR-T product designed to target both CD19+ B cells and CD70+ activated T cells, which are key drivers of autoimmune disease. The therapy incorporates the company's Dagger® technology, which aims to reduce or eliminate the need for lymphodepletion to facilitate broader CAR-T adoption in autoimmune indications.
Initial clinical and biomarker data are now expected in the first half of 2026, approximately six months later than originally planned. Management cited added complexity in site staffing and multidisciplinary requirements as key contributors to the delay.
Solid Tumor Progress with Partnership Potential
ALLO-316, targeting renal cell carcinoma (搜索) (RCC), completed Phase 1b enrollment and is described as the only allogeneic CAR-T therapy to show potential in solid tumors. The company presented updated Phase 1b cohort data at the 2025 American Society of Clinical Oncology (ASCO) Annual Meeting.
According to prior interim data presented at SITC in November 2024, fifty percent of patients with high expression of the target protein CD70 (搜索) who had exhausted other treatment options responded to treatment. Following the latest trial results, the company has met with the FDA to align on pivotal trial design and has begun discussions regarding potential partnerships to advance the program.
Manufacturing and Operational Strengths
The company's manufacturing infrastructure, specifically its Cell Forge 1 facility, continues to provide sufficient inventory to supply ongoing trials for all leading product candidates. Previous cost-saving measures in manufacturing have not affected clinical supply, and the company continues routine stability testing to ensure adequate shelf life for its off-the-shelf products.
Allogene's approach focuses on developing allogeneic, or "off-the-shelf," CAR-T therapies using engineered healthy donor T cells to target and destroy cancer or harmful immune cells. This strategy aims to provide options that are ready-made and scalable, unlike traditional personalized cell therapies that require individualized cell harvesting.